The Use of Cannabidiol in Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-15

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alternative and complementary medicines (MAC) are commonly used by cancer patients to help them to face with anticancer treatment, reduce oncology symptoms and/or anticancer treatment adverse effects, detoxifying the body. In consistence with guidelines from the French Society for Oncology Pharmacy (SFPO), the pharmaceutical consultation includes a discussion and collection of herbs, botanical and other natural products consumed by cancer patients. This aim to prevent and manage herb-drug interaction as well as other drug-related problems (DRP). The recent French experimentation dedicated to cannabidiol for medical use could enhance interest of cancer patients in the field of MAC. However, cannabidiol have shown inhibitory effect on different cytochromes with a risk of HDI as other MAC. While the prevalence of MAC consumption is already known in some type of cancer, the consumption of CBD is less known and should be explored. Through this study we wish to know the prevalence of cannabidiol consumption in cancer patients and to establish a typical profile as well as to know the modalities of use. We also want to validate a questionnaire through a literacy scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study

NCT05836857

Cancer

ACTIVE_NOT_RECRUITING

A Study: Pure CBD as Single-agent for Solid Tumor.

NCT02255292

Solid Tumor

UNKNOWN PHASE2

Patient Reported Symptom Control With THC or CBD Use

NCT04875286

Cancer-Associated Pain Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

ACTIVE_NOT_RECRUITING

Cannabis Use Patterns Among Cancer Patients

NCT05132842

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

COMPLETED

Cannabis for Palliative Care in Cancer

NCT06266611

Sleep Anxiety Depression +1 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* A Prospective observational study
* Conducted in an oncology day-hospital (CHU de Reims)

All data collected were:

* Clinical characteristics,
* Administrative data,
* Medication review,
* Biologic data collection,
* Oncological data,
* Disease data

Statistical analysis:

* Quantitative variables: described as mean ± standard deviation (SD) or median (Interquartile range and minimum and maximum)
* Student test and Fischer exact performed to compare CBD users and non-users.
* Analysis of variance: used to compare scores between different variables
* Univariate logistic and multivariate logistic regressions were performed. Variables with a p-value \< 0.20 (Wald test) in the univariable analyses were considered eligible for the multivariable models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CBD users

Non applicable

Intervention Type OTHER

Non Applicable

CBD non-users

Non applicable

Intervention Type OTHER

Non Applicable

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non applicable

Non Applicable

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Patients who received anticancer drug with very short administration time (typically subcutaneous anticancer drugs as 5-azacitidine, bortezomib and some monoclonal antibodies)
* Patients who were not able to speak and understand French as well as who were unable to communicate clearly.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No